Treating Blood Cancers

Recent Episodes

Key Insights from Attending ASH 2025

Posted January 13, 2026 • 00:33:51

Lore Gruenbaum, PhD, Blood Cancer United, Washington, DC Recorded on December 18, 2025 Lore Gruenbaum, PhD Chief Scientific Officer & Senior Vice President of Research Blood Cancer United Washington, DC Join Dr. Lore Gruenbaum, Chief Scientific Officer and Senior Vice President of Research at Blood Cancer United, to provide practice-changing data in hematologic malignancies from the 67th American Society of Hematology (ASH) Annual Meeting. Explored are breakthroughs in multiple myeloma, AML, CLL, and advances in cell therapy. Discussion also covers the growing use of artificial intelligence to accelerate precision medicine, spotlighting the Blood Cancer United Beat AML® Master Clinical Trial as a model for AI-driven trial design and real-time clinical decision-making. Tune in today for the key takeaways you need to know! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Resources for Patients

Delivering Equitable Cancer Care: What Every Healthcare Professional Should Know

Posted December 17, 2025 • 00:30:48

Raymond Mailhot, MD, MPH, University of Miami, Miami, FL Recorded on December 2, 2025 Raymond Mailhot, MD, MPH Department of Radiation Oncology University of Miami Miami, FL Join us with Dr. Raymond Mailhot from the University of Miami as we explore how social determinants of health shape patient experiences, treatment decisions, and outcomes. He discusses the importance of cultural competence in delivering equitable, patient-centered care and shares practical communication strategies to better engage patients and collaborate effectively. This episode offers actionable insights to strengthen relationships and improve overall care quality. Tune in today to gain practical strategies that will enhance your approach to patient-centered care and drive better outcomes! Additional Blood Cancer United Resources: Blood Cancer United Accredited and Non-Accredited Healthcare Professional Education Blood Cancer United Medical Debt Case Management Program for Patients Blood Cancer United Additional Resources for Patients

Hairy Cell Leukemia: Strategies for Improved Patient Outcomes

Posted November 20, 2025 • 00:40:10

Paul J. Hampel, MD, Mayo Clinic, Rochester, MN Recorded on November 4, 2025 Paul J. Hampel, MD Assistant Professor of Medicine Division of Hematology, Department of Medicine Mayo Clinic Rochester, MN In this episode, Dr. Paul Hampel from Mayo Clinic Rochester takes a comprehensive look at hairy cell leukemia (HCL). He reviews the current diagnostic work-up, including immunophenotypic and molecular testing, and highlights key clinical features that distinguish HCL from related disorders. Dr. Hampel also discusses approved frontline therapies and evidence-based approaches for relapsed or refractory disease, with attention to infection risk and supportive care. The conversation explores emerging agents, novel combinations, and clinical trials shaping the next wave of HCL management. Join us for this expert discussion, offering practical insights to enhance care and outcomes for patients with HCL.

Managing CML: What HCPs Need to Know

Posted November 6, 2025 • 00:37:19

Michael J. Mauro, MD, Memorial Sloan Kettering Cancer Center, New York, NY Recorded on October 23, 2025 Michael J. Mauro, MD Director, Chronic Myeloid Leukemia Program Professor of Medicine, Leukemia Service Memorial Sloan Kettering Cancer Center New York, NY Tune in for this expert-led discussion with Dr. Michael Mauro from Memorial Sloan Kettering Cancer Center on the evolving management of chronic myeloid leukemia (CML) in the era of tyrosine kinase inhibitors (TKIs) and newly approved FDA therapies. Dr. Mauro explores how TKIs have transformed prognosis, key factors guiding initial therapy selection, and best practices for managing treatment-related side effects. He also shares updates on TKI discontinuation criteria, long-term monitoring, and a forward look at ongoing trials and emerging therapeutic advances shaping the future of CML care. Gain actionable insights to enhance patient outcomes today!

Understanding MRD: Insights for clinical practice and patient care

Posted October 10, 2025 • 00:32:23

Rahul Banerjee, MD, FACP, Fred Hutchinson Cancer Center, Seattle, WA Recorded on September 25, 2025 Rahul Banerjee, MD, FACP Assistant Professor Fred Hutchinson Cancer Center Seattle, WA In this episode, Dr. Rahul Banerjee from Fred Hutchinson Cancer Center in Seattle, WA, discusses the evolving role of measurable residual disease (MRD) in hematologic malignancies. He explores what MRD is, how assays are used and interpreted, and its impact across the disease continuum. The conversation also covers MRD’s role in clinical trials, how to effectively explain MRD to patients, practical considerations for testing in community settings, and key education resources for both healthcare professionals and patients. Tune in today to gain practical insights you can apply in your daily practice! This episode is supported by Adaptive Biotechnologies Corporation and Allogene Therapeutics.